How much funding has Transcode Therapeutics, Inc. raised?

Transcode Therapeutics, Inc. has raised $33.0M in total funding, most recently a Series B round.

Who are Transcode Therapeutics, Inc.'s investors?

Transcode Therapeutics, Inc.'s investors include CK Life Sciences.

When was Transcode Therapeutics, Inc. founded?

Transcode Therapeutics, Inc. was founded in 2021.

Where is Transcode Therapeutics, Inc. headquartered?

Transcode Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States.

What industry is Transcode Therapeutics, Inc. in?

Transcode Therapeutics, Inc. operates in Biotech, Drug Discovery, Healthcare.

How many employees does Transcode Therapeutics, Inc. have?

Transcode Therapeutics, Inc. has 1-10 employees.

Transcode Therapeutics, Inc.

Delivering a Cancer-Free Future

Boston, United States · Founded 2021 · $33.0M raised

Biotech

Drug Discovery

Healthcare

Headquarters: Boston, Massachusetts
Employees: 1–10
Founded: 2021
Business Model: B2B

Website: transcodetherapeutics.com
Total Funding: $33.0M
Last Round: $25.0M Series BOct 2025
Rounds: 2

About

TransCode Therapeutics is a clinical-stage RNA oncology company developing iron oxide nanoparticle-based therapeutics to treat metastatic cancer. Its lead candidate TTX-MC138 targets microRNA-10b, a master regulator of metastasis, with applicability across 18+ cancer types including breast, pancreatic, and ovarian cancer. The company has received multi-year NIH SBIR Fast-Track funding to support clinical evaluation.

Summary

Transcode Therapeutics, Inc. is a Biotech company based in Boston, United States, founded in 2021. It has raised $33.0M in total across 2 rounds, most recently a $25.0M Series B round in Oct 2025. Investors include CK Life Sciences.

LinkedIn X (Twitter)